Another perspective

Anonymous, computer-generated comments from attendees at the Houston Colorectal Cancer Patient Meeting

Section A: Overview of patients participating in the survey

Section B: The initial diagnosis, consultation with a medical oncologist

Section C: Risks and benefits of adjuvant chemotherapy

Section D: Clinical trial participation

Section E: Recovery from chemotherapy, prevention of a second colorectal cancer

Section F: Patient grading of physicians and educational needs for patients

Section G: Bibliography

SELECT PUBLICATIONS

1. Breast Cancer Update Patterns of Care in Medical Oncology 2005;2(3).

2. Love NH et al. Heterogeneity in breast cancer survivors’ perceptions of adjuvant systemic therapy options after verbal counseling from a physician panel in a “town meeting.” San Antonio Breast Cancer Symposium 2003;Abstract 142.

3. Love NH et al. How do prostate cancer survivors perceive treatment trade-offs for hypothetical clinical situations? Proc AUA 2003. No abstract available

4. Love N et al. Influence of prior therapy on breast cancer survivors’ preferences for adjuvant systemic therapy in hypothetical scenarios. Proc ASCO 2004;Abstract 591.

5. Love NH et al. A “report card” on medical oncologists and oncology nurses: Survey of patients with metastatic breast cancer and companion surveys of medical oncologists and oncology nurses. San Antonio Breast Cancer Symposium 2004;Abstract 3069.

6. Stanley KJ et al. A report card on oncology nurses: Survey of patients with metastatic breast cancer. Oncology Nursing Society Congress 2005;Abstract 64.

7. Love NH et al. Preferences for oral versus parenteral antitumor therapy: A survey of patients with metastatic breast cancer. Oncology Nursing Society Congress 2005;656. Abstract

8. Paley M et al. Preferences for oral and parenteral antitumor therapy: A survey of 260 patients with metastatic breast cancer. Proc ASCO 2005;Abstract 619.

9. Love N et al. Perspectives of patients with colorectal cancer (PCRC): A pilot project to determine interests in and understanding of patient education on clinical research. Proc ASCO 2005;Abstract 3635.

10. Meyerhardt JA et al. The impact of physical activity on patients with stage III colon cancer: Findings from Intergroup trial CALGB 89803. Proc ASCO 2005;Abstract 3534.

11. Blend MJ. Can we learn from our patients? Perspect Biol Med 2005;48(1):138-42. Abstract

12. Couture J et al. Patient’s preferences for adjuvant postoperative chemoradiation therapy in rectal cancer. Dis Colon Rectum 2005;48(11):2055-60. Abstract

13. Solomon MJ et al. What do patients want? Patient preferences and surrogate decision making in the treatment of colorectal cancer. Dis Colon Rectum 2003;46(10)1351-7. Abstract

14. Jansen SJ et al. Review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol 2004;(15):3181-90. Abstract

15. Beale P et al. Adjuvant chemotherapy (ACT) for early colon cancer (ECC): What do investigators think makes it worthwhile? Proc ASCO 2004;Abstract 6112.

16. Baddi L, Benson A 3rd. Adjuvant therapy in stage II colon cancer: Current approaches. Oncologist 2005;10(5):325-31. Abstract

17. Benson AB 3rd et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer. J Clin Oncol 2004;22(16):3408-19. Abstract

18. Van Cutsem E, Costa F. Progress in the adjuvant treatment of colon cancer: Has it inf luenced clinical practice? JAMA 2005;294(21):2758-60. Abstract

19. Diaz-Rubio Garcia E et al. A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer. Clin Transl Oncol 2005;7(1):3-11. Abstract

20. Gill S, Goldberg RM. Duration of adjuvant therapy for colorectal cancer: Are we overtreating our patients? Nat Clin Pract Oncol 2005;2(6):276-7. No abstract available

21. Golfinopoulos V et al. Treatment of colorectal cancer in the elderly: A review of the literature. Cancer Treata Rev 2005;[Epub ahead of print]. Abstract

22. Hobday TJ. An overview of approaches to adjuvant therapy for colorectal cancer in the United States. Clin Colorectal Cancer 2005;5(Suppl 1):11-8. Abstract

23. Iacopetta B. A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy. Ann Oncol 2002;13(9):1510. No abstract available

24. Johnston PG. Stage II colorectal cancer: To treat or not to treat. Oncologist 2005;10(5):332-4. No abstract available

25. Lawes D, Taylor I. Chemotherapy for colorectal cancer — An overview of current management for surgeons. Eur J Surg Oncol 2005;31(9):932-41. Abstract

26. Midgley R, Kerr DJ. Adjuvant chemotherapy for stage II colorectal cancer: The time is right! Nat Clin Pract Oncol 2005;2(7):364-9. Abstract

27. Ong S et al. Predictors of referral for adjuvant therapy for colorectal cancer. Can J Surg 2005;48(3):225-9. Abstract

28. Sobrero A et al. New directions in the treatment of colorectal cancer: A look to the future. Eur J Cancer 2000;36(5):559-66. Abstract

29. Sonpavde G. Communicating the value of adjuvant chemotherapy. J Clin Oncol 2003;21(5):948-9. No abstract available

30. Sun W, Haller DG. Adjuvant therapy for colon cancer. Curr Oncol Rep 2005;7(3):181-5. Abstract

31. Andre T et al; Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350(23):2343-51. Abstract

32. De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.

33. De Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of Stage II and Stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc ASCO 2005;Abstract 3501.

34. Grothey A, Sargent DJ. FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancer. J Clin Oncol 2005;23(15):3311-3. No abstract available

35. Scheithauer W et al; X-ACT Study Group. Oral capecitabine as an alternative to iv 5- f luorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. Ann Oncol 2003;14(12):1735-43. Abstract

36. Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704. Abstract

37. Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Proc ASCO 2005;Abstract 3521.

38. Choi J et al. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 2006;17(1):103-5. Abstract

39. Diaz-Rubio E, Schmoll HJ. The future development of bevacizumab in colorectal cancer. Oncology 2005;69(Suppl 3):34-45. Abstract

40. Ellis PM. Attitudes towards and participation in randomised clinical trials in oncology: A review of the literature. Ann Oncol 2000;11(8):939-45. Abstract

41. Sorensen JB et al. Patient-physician communication concerning participation in cancer chemotherapy trials. Br J Cancer 2004;90(2):328-32. Abstract

42. Porter GA et al. Access to care and satisfaction in colorectal cancer patients. World J Surg 2005;29(11):1444-51. Abstract